Could a new pill tame adult ADHD symptoms?

NCT ID NCT07755410

Recruiting now Disease control Sponsor: Alkermes, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether an experimental tablet called ALKS 7290 can reduce ADHD symptoms in adults. About 312 adults with ADHD will take either the drug or a placebo daily for 4 weeks. Researchers will measure changes in symptom scores and watch for side effects to see if the drug is safe and potentially effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALKS 7290 tablets taken daily by mouth
What this could lead to: If successful, this could point toward a new daily medication option for adults with ADHD, potentially offering better symptom control with fewer side effects.
What could go wrong: This is an early-phase trial with a small number of participants and a short 4-week treatment period. It may not show a clear benefit over placebo, and the drug could have side effects that outweigh its advantages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY (ADHD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY (ADHD)

Contacts and locations

Locations

Alkermes Investigator Site
RECRUITING

Chino, California, 91710, United States
Alkermes Investigator Site
RECRUITING

Maitland, Florida, 32751, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.